THE Food and Drug Administration, FDA, has approved a new product that protects prostate cancer patients from the side effects of radiation. Prostate cancer is the most diagnosed cancer in men in Nigeria.
Called SpaceOAR (Space Organs At Risk), it is a hydrogel used as a spacer to protect the rectum, bladder and intestines in men undergoing prostate cancer (PCa) radiotherapy.
The SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for PCa, creating space to protect the anterior rectum (the Organ At Risk) from radiation exposure.
Placed through a small needle, the hydrogel is administered as a liquid, but quickly solidifies into a soft gel that expands the space between the prostate and rectum. The hydrogel spacer maintains this space until radiotherapy is complete